Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe Gets FDA Emergency Use Authorization for Flu Test

NEW YORK (GenomeWeb News) – Gen-Probe today said that the US Food and Drug Administration has granted an Emergency Use Authorization for the firm's Prodesse ProFlu-ST assay for use in CLIA high-complexity labs for diagnosis of 2009 H1N1 influenza virus infection.

The FDA granted the EUA for use of the test "aided by an algorithm that relies on seasonal influenza A/H1 virus and seasonal influenza A/H3 virus results, from a single sample in individuals who are diagnosed with influenza A by currently available FDA-cleared or authorized devices."

The test uses real-time PCR to detect the virus and return results in as little as three hours. The ProFlu-ST was developed by Prodesse, which recently was acquired by Gen-Probe for at least $60 million.

"This test complements nicely our FDA cleared ProFlu+ Assay, which from a single sample, detects and discriminates influenza A virus, influenza B virus and RSV," Andy Shrago, head of marketing for Prodesse products, said in a statement.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.